Nasal spray could deliver brain tumor treatment directly to Kids' tumors
NCT ID NCT06357377
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, and tumor samples will be tested for the drug if surgery is already planned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NEO100 (a purified form of perillyl alcohol, a natural compound)
- What this could lead to
- If it works, this could point toward a new way to deliver treatment directly to brain tumors through the nose, potentially reducing side effects.
- What could go wrong
- This is a very early, small Phase 1b trial with only 12 participants, focused on safety and dosing. It may not show any benefit, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOROID PLEXUS CARCINOMA, CHILDHOOD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can trained immune cells outsmart brain tumors?
- Could cutting a wider margin around brain tumors extend survival?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can engineered immune cells tackle an incurable childhood brain tumor?
- Can a 7-Week brain tumor treatment beat the standard 10-Week plan?
- Could an antiparasitic drug boost radiation against childhood brain tumors?